ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

3:00PM-4:30PM: Abstract Number: 2655

Diagnostic Challenges of Dermatomyositis: A Retrospective Study of Its Dermatologic Mimics and Misdiagnoses

Abstracts: ARP Interprofessional II: Psychology & Practice

3:00PM-4:30PM: Abstract Number: 2635

Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Appropriateness of Rheumatology Referrals and Treatment Outcomes

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II

3:00PM-4:30PM: Abstract Number: 2609

Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry

Abstracts: Health Services Research II

3:00PM-4:30PM: Abstract Number: 2620

Education and Medication Access Needs in Rheumatology Patients Starting New Medications: Quality Improvement Data from a Pharmacist Intervention

Abstracts: Measures & Measurement of Healthcare Quality

3:00PM-4:30PM: Abstract Number: 2608

Evolution of Rheumatoid Arthritis Pharmacotherapy: A Ten-Year Analysis of Biologic and Targeted Synthetic DMARD Use and Its Predictors in a National Sample of Rheumatology Practices

Abstracts: Health Services Research II

3:00PM-4:30PM: Abstract Number: 2639

Exploring Weight Trends in Psoriatic Arthritis: Unraveling Effects of Drugs

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II

3:00PM-4:30PM: Abstract Number: 2650

Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Complications in Giant Cell Arteritis

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II

3:00PM-4:30PM: Abstract Number: 2632

Genetically-engineered Ro-specific Regulatory T Cells to Treat Primary Sjögren’s Disease

Abstracts: Sjögren's Syndrome – Basic & Clinical Science

3:00PM-4:30PM: Abstract Number: 2602

Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus

Abstracts: SLE – Etiology & Pathogenesis

3:00PM-4:30PM: Abstract Number: 2617

Higher Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures, Analysis of Data from 2020 – 2022

Abstracts: Measures & Measurement of Healthcare Quality

3:00PM-4:30PM: Abstract Number: 2645

Human NCF1-p.R90H Variant Promotes Pulmonary Fibrosis in the Bleomycin-induced Mouse Model and Systemic Sclerosis Patients via Expansion of SPP1+Monocytes-derived Macrophages

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II

3:00PM-4:30PM: Abstract Number: 2658

Hypovitaminosis D in Lupus Nephitis

Abstracts: ARP Interprofessional II: Psychology & Practice

3:00PM-4:30PM: Abstract Number: 2630

Identification of Molecular Biomarkers for Sjögren’s Disease Stratification via a Deep Learning Foundation Model Dedicated to Immune-Mediated and Inflammatory Disease

Abstracts: Sjögren's Syndrome – Basic & Clinical Science

3:00PM-4:30PM: Abstract Number: 2641

Identification of Systemic Sclerosis Intrinsic Subtypes in the ASSET Clinical Trial Using PBC Gene Expression

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II

3:00PM-4:30PM: Abstract Number: 2626

Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion

Abstracts: Pediatric Rheumatology – Clinical II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].